Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.

In English

Författare

  • Peter Johansson
  • Lauren G Aoude
  • Karin Wadt
  • William J Glasson
  • Sunil K Warrier
  • Alex W Hewitt
  • Jens Folke Kiilgaard
  • Steffen Heegaard
  • Tim Isaacs
  • Maria Franchina
  • Christian Ingvar
  • Tersia Vermeulen
  • Kevin J Whitehead
  • Christopher W Schmidt
  • Jane M Palmer
  • Judith Symmons
  • Anne-Marie Gerdes
  • Göran B Jönsson
  • Nicholas K Hayward
Visa allt

Summary, in English

Next generation sequencing of uveal melanoma (UM) samples has identified a number of recurrent oncogenic or loss-of-function mutations in key driver genes including: GNAQ, GNA11, EIF1AX, SF3B1 and BAP1. To search for additional driver mutations in this tumor type we carried out whole-genome or whole-exome sequencing of 28 tumors or primary cell lines. These samples have a low mutation burden, with a mean of 10.6 protein changing mutations per sample (range 0 to 53). As expected for these sun-shielded melanomas the mutation spectrum was not consistent with an ultraviolet radiation signature, instead, a BRCA mutation signature predominated. In addition to mutations in the known UM driver genes, we found a recurrent mutation in PLCB4 (c.G1888T, p.D630Y, NM_000933), which was validated using Sanger sequencing. The identical mutation was also found in published UM sequence data (1 of 56 tumors), supporting its role as a novel driver mutation in UM. PLCB4 p.D630Y mutations are mutually exclusive with mutations in GNA11 and GNAQ, consistent with PLCB4 being the canonical downstream target of the former gene products. Taken together these data suggest that the PLCB4 hotspot mutation is similarly a gain-of-function mutation leading to activation of the same signaling pathway, promoting UM tumorigenesis.

Avdelning/ar

Publiceringsår

2016

Språk

Engelska

Sidor

4624-4631

Publikation/Tidskrift/Serie

Oncotarget

Volym

7

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

Impact Journals

Ämne

  • Cancer and Oncology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1949-2553